Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs - Université d'Évry Access content directly
Journal Articles Molecular Therapy Year : 2017

Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs

David Mack
  • Function : Author
Virginie Latournerie
  • Function : Author
Jessica Snyder
  • Function : Author
Matthew Elverman
  • Function : Author
Jérôme Denard
Laurine Buscara
  • Function : Author
Christine Le Bec
  • Function : Author
Jean-Yves Hogrel
  • Function : Author
  • PersonId : 901910
Annie Brezovec
  • Function : Author
Hui Meng
  • Function : Author
Fujun Liu
  • Function : Author
Michael O'Callaghan
  • Function : Author
Nikhil Gopal
  • Function : Author
Valerie Kelly
  • Function : Author
Barbara Smith
  • Function : Author
Ana Strande
  • Function : Author
Fulvio Mavilio
Michael Lawlor
  • Function : Author
Ana Buj-Bello
Michael O’callaghan
  • Function : Author
Jennifer Strande
  • Function : Author

Abstract

X-linked myotubular myopathy (XLMTM) results from MTM1 gene mutations and myotubularin deficiency. Most XLMTM patients develop severe muscle weakness leading to respiratory failure and death, typically within 2 years of age. Our objective was to evaluate the efficacy and safety of systemic gene therapy in the p.N155K canine model of XLMTM by performing a dose escalation study. A recombinant adeno-associated virus serotype 8 (rAAV8) vector expressing canine myotubularin (cMTM1) under the muscle-specific desmin promoter (rAAV8-cMTM1) was administered by simple peripheral venous infusion in XLMTM dogs at 10 weeks of age, when signs of the disease are already present. A comprehensive analysis of survival, limb strength, gait, respiratory function, neurological assessment, histology, vector biodistribution, transgene expression, and immune response was performed over a 9-month study period. Results indicate that systemic gene therapy was well tolerated, prolonged lifespan, and corrected the skeletal musculature throughout the body in a dose-dependent manner, defining an efficacious dose in this large-animal model of the disease. These results support the development of gene therapy clinical trials for XLMTM.
Fichier principal
Vignette du fichier
main.pdf (2.97 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-02179363 , version 1 (09-11-2023)

Identifiers

Cite

David Mack, Karine Poulard, Melissa Goddard, Virginie Latournerie, Jessica Snyder, et al.. Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs. Molecular Therapy, 2017, 25 (4), pp.839-854. ⟨10.1016/j.ymthe.2017.02.004⟩. ⟨hal-02179363⟩
205 View
14 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More